ZNF629

Across TCGA pan-cancer cohorts, ZNF629 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF629 data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZNF629 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ZNF629 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, GBM, and LSCC are the cancer types where ZNF629 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	1.000	0.645	.002	16	view →
GBM	DFS	Tertile	All	0.481	0.270	.013	14	view →
LSCC	DFS	Quartile	All	0.834	0.534	.018	9	view →
CCRCC	OS	Median	II,III,IV	0.454	1.000	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZNF629–LUAD (OS)

Open the LUAD breakdown →